News AstraZeneca spins out biotech to focus on autoimmune candida... AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.
News UK pharma has concerns about the new NHS 10-year plan The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face